BridgeBio Pharma, Inc. - Common Stock · Transaction May 11, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
XNAS · BBIO
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
BridgeBio Pharma, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
$66.91
Follow $BBIO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $BBIO by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET · BBIO
MethodologyBBIO
BridgeBio Pharma, Inc. Common Stock
Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
41/ 100
Veridion Score
Lower range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 1 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is BBIO moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About BridgeBio Pharma, Inc. Common Stock
PHARMACEUTICAL PREPARATIONSListed since
2019
Employees
839
Country
US
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$66.91
Last session
Day high
$66.91
Last session
Day low
$66.91
Last session
Previous close
$66.91
52W high
$90.17
-25.80% from high
52W low
$52.86
38% of range
Market cap
$13.1B
EPS
$-3.4500
Beta
0.45
Shares out
195.5M
Avg volume
2.5M
VWAP
$66.91
Last session
Price history computed in-house
1W
+2.04%
1M
-12.54%
3M
-13.32%
1Y
+25.58%
YTD
-12.52%
SMA 50 $76.63 · below
SMA 200 $73.61 · below
52W position 38%
BBIO overview
Related filings and maps
Public disclosures
Congress activity in BBIO
Official filing ↗
BridgeBio Pharma, Inc. - Common Stock · Transaction Apr 29, 2026 · Filed May 8, 2026 · $1,001 to $15,000
BridgeBio Pharma, Inc. - Common Stock · Transaction Mar 19, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
BridgeBio Pharma, Inc. - Common Stock · Transaction Mar 18, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
BridgeBio Pharma, Inc. - Common Stock · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
Federal contracts
BBIO contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for BBIO in this window.
Lobbying spend
BBIO lobbying filings, year to date.
Registered lobbying filings matched to BridgeBio Pharma, Inc. Common Stock.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for BBIO in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for BBIO.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.